• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sight Sciences, Inc. - Common Stock (NQ:SGHT)

7.110 +1.560 (+28.11%)
Streaming Delayed Price Updated: 11:40 AM EDT, Aug 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sight Sciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Sight Sciences Appoints Ali Bauerlein as Chief Financial Officer
April 03, 2023
From Sight Sciences, Inc.
Via GlobeNewswire
News headline image
Sight Sciences Defeats Invalidity Challenges Filed By Alcon and Ivantis In The U.S. Patent Office
March 30, 2023
From Sight Sciences, Inc.
Via GlobeNewswire
News headline image
Sight Sciences Reports Fourth Quarter and Full Year 2022 Financial Results
March 13, 2023
From Sight Sciences, Inc.
Via GlobeNewswire
News headline image
A Preview Of Sight Sciences's Earnings ↗
March 10, 2023
 
Via Benzinga
News headline image
Sight Sciences Launches the Ergo-Series of the OMNI® Surgical System
March 09, 2023
The Ergo-Series maximizes ergonomics and surgical ease-of-use while continuing to enable surgeons to perform minimally invasive, implant-free glaucoma procedures 
From Sight Sciences, Inc.
Via GlobeNewswire
News headline image
Glaucoma Is The Second Leading Cause Of Blindness Globally – Skye Bioscience Appears To Be Making Rapid Progress In The Development Of Their Candidate To Treat It ↗
March 09, 2023
Biomed company Skye Bioscience (OTCQB: SKYE) has seen positive results in its clinical research so far and is preparing for the next stage in the development of its therapy for eye disease.  
Via Benzinga
News headline image
Sight Sciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 13, 2023
February 23, 2023
From Sight Sciences, Inc.
Via GlobeNewswire
News headline image
Sight Sciences to Present at the Upcoming Citi 2023 Healthcare Services, Medtech, Tools & HCIT Conference
February 22, 2023
From Sight Sciences, Inc.
Via GlobeNewswire
News headline image
3 Prime Healthcare Takeover Targets ↗
February 14, 2023
These three companies are attractive targets for their potential. 
Via The Motley Fool
News headline image
Lions Gate Entertainment, DexCom, Yelp And Other Big Stocks Moving Higher On Friday ↗
February 10, 2023
U.S. stocks traded mixed, with the Nasdaq Composite dropping around 100 points on Friday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
News headline image
Sight Sciences Announces 1,000th TearCare® Customer Installation
January 26, 2023
Over 1,000 Professional Eye Care Practices Have integrated the TearCare® System to Treat Root Cause of Dry Eye Disease due to Meibomian Gland Dysfunction (MGD) 
From Sight Sciences, Inc.
Via GlobeNewswire
News headline image
Super Micro Computer, Rayonier Advanced Materials And Some Other Big Stocks Moving Lower On Tuesday ↗
January 10, 2023
U.S. stocks traded slightly higher, with the Dow Jones gaining around 30 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
News headline image
Sight Sciences Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Financial Results
January 09, 2023
Company Also Announces CFO Transition 
From Sight Sciences, Inc.
Via GlobeNewswire
News headline image
Dow Rises Over 300 Points; US Adds 223,000 Jobs In December ↗
January 06, 2023
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 300 points on Friday. 
Via Benzinga
News headline image
Skye Bioscience (OTCQB: SKYE) Heads Into 2023 As A Clinical-Stage Company After Dosing Its First Human Participants ↗
December 22, 2022
This year has been quite busy for Skye Bioscience Inc. (OTCQB: SKYE). 
Via Benzinga
News headline image
Why Spruce Biosciences Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
January 06, 2023
Gainers Swvl Holdings Corp. (NASDAQ: SWVL) surged 133% to $0.3218. Swvl recently announced the commencement of a strategic review process. 
Via Benzinga
News headline image
Improvements in Signs and Symptoms of Dry Eye Disease From a Single TearCare® Treatment Sustained Through 12 Months
December 08, 2022
From Sight Sciences, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2023 ↗
January 06, 2023
 
Via Benzinga
News headline image
Sight Sciences to Present at the Upcoming Piper Sandler 34th Annual Healthcare Conference
November 22, 2022
From Sight Sciences, Inc.
Via GlobeNewswire
News headline image
Unity Software, Amazon, Doximity And Other Big Gainers From Friday ↗
November 14, 2022
U.S. stocks closed higher on Friday, with the Nasdaq Composite jumping more than 200 points. Here is the list of some big stocks recording gains in the previous session. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
November 11, 2022
Gainers 
Via Benzinga
News headline image
Why Tattooed Chef Shares Dipped Around 15%; Here Are 95 Biggest Movers From Friday ↗
November 14, 2022
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares surged 56.6% to settle at $19.10 on Friday. 
Via Benzinga
News headline image
Dow Turns Higher; Nasdaq Jumps Over 200 Points ↗
November 11, 2022
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 60 points on Friday. 
Via Benzinga
News headline image
Why Compass Shares Are Trading Higher By Over 56%? Here Are 63 Stocks Moving In Friday's Mid-Day Session ↗
November 11, 2022
Gainers Snail, Inc. (NASDAQ: SNAL) shares jumped 74.9% to $3.9350 after the company announced a $5 million share repurchase program. 
Via Benzinga
News headline image
Nasdaq Surges 100 Points; Crude Oil Rises Sharply ↗
November 11, 2022
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining 100 points on Friday. 
Via Benzinga
News headline image
US Stocks Mixed Following Thursday's Rally; Dow Drops 50 Points ↗
November 11, 2022
U.S. stocks traded mixed this morning on Friday, after the Dow Jones jumped 1,200 points in the previous session. 
Via Benzinga
News headline image
Sight Sciences Reports Third Quarter 2022 Financial Results
November 10, 2022
From Sight Sciences, Inc.
Via GlobeNewswire
News headline image
Sight Sciences Announces Publication of Clinical Data Demonstrating Standalone Effectiveness of the OMNI® Surgical System in Pseudophakic Glaucoma Patients with Uncontrolled Pressure Following a Previous Combination Cataract Stent Procedure
November 03, 2022
Multicenter Clinical Data from Five US sites Published in International Ophthalmology 
From Sight Sciences, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For November 10, 2022 ↗
November 10, 2022
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report earnings for its third quarter. 
Via Benzinga
News headline image
Sight Sciences to Report Third Quarter 2022 Financial Results on November 10, 2022
October 20, 2022
From Sight Sciences, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap